Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | RGS12 | O14924 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070915 | 1.00 | PTGS2 (0.74) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8875517 | 1.00 | PTGS2 (0.74) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29749112 | 1.00 | PTGS2 (0.74) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29454970 | 1.00 | PTGS2 (0.74) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8879040 | 0.91 | PTGS2 (0.67) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8878227 | 0.90 | LMNA (0.63) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8879445 | 0.90 | PTGS2 (0.65) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8876660 | 0.90 | PTGS2 (0.65) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8877597 | 0.89 | PTGS2 (0.72) | PTGS2LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8876621 | 0.89 | LMNA (0.61) | PTGS2LMNACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350093-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORPORATION (US) | 2019-07-16 | — | — | US | claimed |
| WO-1996037467-A1 | N-BENZYLINDOL-3-YL BUTANOIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-11-28 | — | — | WO | claimed |
| US-20200188142-A1 | DEGRADABLE IMPLANTABLE MEDICAL DEVICES | ELIXIR MEDICAL CORPORATION (US) | 2020-06-18 | — | — | US | disclosed |
| US-10350093-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORPORATION (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2016177776-A1 | BIOMARKERS FOR THE DETECTION OF ASPIRIN INSENSITIVITY | ACADEMISCH MEDISCH CENTRUM (NL) | 2016-11-10 | — | — | WO | disclosed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-5639780-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-06-17 | — | — | US | disclosed |
| WO-1996037467-A1 | N-BENZYLINDOL-3-YL BUTANOIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | BPGM, PLG, FGB | PTGS2 372/4885LMNA 635/4885CYP1A2 3194/4885 |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | PTGS2 433/4885LMNA 3303/4885CYP1A2 1667/4885 |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885LMNA 3292/4885CYP1A2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.